# Dose-escalation of Rectal Indomethacin for Preventing PEP

> **NCT07247682** · PHASE4 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Anhui Medical University** · enrollment: 1036 (estimated)

## Conditions studied

- Post-ERCP Pancreatitis

## Interventions

- **DRUG:** standard-dose group VS high-dose group

## Key facts

- **NCT ID:** NCT07247682
- **Lead sponsor:** The First Affiliated Hospital of Anhui Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2028-12-01
- **Final completion:** 2028-12-30
- **Target enrollment:** 1036 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07247682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07247682, "Dose-escalation of Rectal Indomethacin for Preventing PEP". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07247682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*